MUC16 and cancer: However, among 10 812 patients with any cancer (2081 [19.2%] with MUC16 variant) who did not receive ICI therapy, there was no difference in OS between MUC16 variant and wild-type groups (HR, 1.06; 95% CI, 0.97-1.15; P = .19).